Medical Technologies
Senseonics Completes Transfer of Eversense 365 Sales to Internal Management and Plans Fully Implantable Sensor
Senseonics has completed the transfer of marketing and sales operations for the Eversense 365 continuous glucose monitor from Ascensia Diabetes Care to its internal teams in the United States and Europe, coinciding with record revenue of $14.5 million in the second quarter. The company is developing a fully implantable version of the sensor capable of communicating directly with a phone for one year.
2026-08-13